Previous research has demonstrated that BCR signaling is chronically active in ABC-DLBCL [20] and that BTK inhibitors are highly effective against ABC-DLBCL malignancies [20,62]. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.